InflaRx(IFRX)
JENA, Germany
BiotechnologyFocus: Antibodies for Inflammation
InflaRx is a life sciences company focused on Antibodies for Inflammation.
Immunology
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
CaCP29, a humanized monoclonal antibody
Drug SafetyClinical Trials (1)
NCT01319903Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29
Phase 1CSU lower dose treatment
Chronic Urticaria, IdiopathicClinical Trials (1)
NCT06555328Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
Phase 2Phase 2
Clinical Trials (1)
NCT03001622Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa
Phase 2IFX-1 low dose
Granulomatosis With Polyangiitis (GPA)Clinical Trials (1)
NCT03712345Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA
Phase 2Cohort A: vilobelimab
Acute Respiratory Distress Syndrome (ARDS)Clinical Trials (1)
NCT06701682JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
Phase 2Cohort C: bevacizumab
Acute Respiratory Distress Syndrome (ARDS)Clinical Trials (1)
NCT06701656JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
Phase 2vilobelimab
Pyoderma GangrenosumClinical Trials (1)
NCT03971643Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum
Phase 2Vilobelimab
SCC - Squamous Cell Carcinoma of SkinClinical Trials (1)
NCT04812535Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.
Phase 2Phase 2
Clinical Trials (1)
NCT03895801Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.
Phase 2Cohort B: paridiprubart
Acute Respiratory Distress Syndrome (ARDS)Clinical Trials (1)
NCT06701669JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
Phase 2Cohort A: vilobelimab
Acute Respiratory Distress Syndrome (ARDS)Clinical Trials (1)
NCT06703073JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
Phase 2Phase 2
Clinical Trials (1)
NCT02866825Studying Complement Inhibition in Complex Cardiac Surgery
Phase 2Phase 2
Clinical Trials (1)
NCT03487276Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
Phase 2CaCP29
Severe SepsisClinical Trials (1)
NCT02246595Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction
Phase 2IFX-1 + BSC
Severe COVID-19 PneumoniaClinical Trials (1)
NCT04333420Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia
Phase 2/3vilobelimab
Pyoderma GangrenosumClinical Trials (1)
NCT05964413Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2023
Portfolio: 16 clinical trials
Top TAs: Respiratory, Dermatology, Infectious Diseases
Publications: 25 in PubMed
Therapeutic Area Focus
Marketed
Pipeline